Sanofi Co-funding the Canadian Consortium for Research on Neurodegeneration

Sanofi is contributing $2.5M dollars to the Canadian Consortium on Neurodegeneration in Aging (CCNA), a new partnership focused on neurodegenerative disease prevention and treatment. The CCNA, which was launched September 10th in Montreal, will bring together 20 research teams to bring new ideas and discoveries to the neurodegenerative space, with a focus on diseases that affect cognition in aging. Sanofi’s funding is directed to two key themes of the CCNA – prevention of cognitive impairment and delaying clinical manifestations of dementia. Hopefully this new effort will leads to new insights on the links between frontotemporal dementia and ALS, and the causes of mild to severe cognitive impairments in up to 50% of people with ALS.

Sanofi is contributing $2.5M dollars to the Canadian Consortium on Neurodegeneration in Aging (CCNA), a new partnership focused on neurodegenerative disease prevention and treatment. The CCNA, which was launched September 10th in Montreal, will bring together 20 research teams to bring new ideas and discoveries to the neurodegenerative space, with a focus on diseases that affect cognition in aging. Sanofi’s funding is directed to two key themes of the CCNA – prevention of cognitive impairment and delaying clinical manifestations of dementia. Hopefully this new effort will leads to new insights on the links between frontotemporal dementia and ALS, and the causes of mild to severe cognitive impairments in up to 50% of people with ALS.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail